The development and evaluation of a tublysine-based antibody-drug conjugate with enhanced tumor therapeutic efficacy

The development and evaluation of a tublysine-based antibody-drug conjugate with enhanced tumor therapeutic efficacy

Antibody-drug conjugates (ADCs) offer targeted cancer therapy by delivering cytotoxic agents directly to tumor cells. However, challenges such as relapse, resistance, and diverse patient needs drive ongoing innovation in ADC development. Exploration of new small-molecule toxins with unique antitumor...

Full description

Bibliographic Details
Main Authors: Huihui Guo, Hongsheng Xie, Yuanyuan Huang, Junxiang Jia, Xiangfei Kong, Qingliang Yang, Shun Gai, Wenjun Li, Lu Bai, Lingli Zhang, Xiaoxiao Chen, Zhicang Ye, Hangbo Ye, Linyao Zhao, Yifang Xu, Yong Du, Xiuzhen Zhang, Miaomiao Chen, Xiaomai Zhou, Robert Y. Zhao
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-02-01
Series:Frontiers in Pharmacology
Subjects:
Tub114
DX126-262
tubulysin B analog
target-specific delivery
HER2
therapeutic window
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2025.1532104/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2025.1532104/full

Similar Items